News

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about APG777 EASI-75 response rates in atopic dermatitis, the unblinding of VYN202 after a safety pause, spesolimab and skin clarity between flares, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

OJM Group’s David Mandell, JD, MBA, shares financial planning strategies for physicians facing new tax laws and market volatility.

Ethanol-based hand sanitizer showed no visible skin toxicity in rats, but subclinical dermatitis raised concerns about dermal test guideline adequacy.

After 4 months of treatment with the dual therapy, patients with refractory vitiligo exhibited an overall 55% remission rate.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

Exclusive Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first half of 2025.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A pilot study evaluates tildrakizumab's safety and potential in treating stable nonsegmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

FDA enhances transparency by publishing over 200 Complete Response Letters, offering insights into drug approval processes and common deficiencies.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Delgocitinib cream offers a safe, effective treatment for chronic hand eczema with minimal systemic absorption, ensuring no significant immunosuppressive effects.

Click here to answer our poll.

Miiskin is transforming dermatologic care through telehealth, enhancing access, efficiency, and patient relationships, according to Ryan Trowbridge, MD, MS, MA, FAAD.

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Achieving optimal treatment targets and minimal disease activity significantly enhances health-related quality of life and satisfaction in patients with atopic dermatitis.

Explore the latest advancements in dermatology in our July issue, from innovative treatments to AI in skin care, shaping the future of skin health and research.

This review of the latest dermatologic studies includes insights into immunomodulatory effects of photodynamic therapy for skin cancer, in vivo and ex vivo sonographic evaluation of tumor margins, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The NEA’s Sam Iannotti, MPH, discusses how the Seal of Acceptance helps patients and clinicians identify products that meet rigorous eczema care standards.

Spesolimab effectively targets the IL-36 receptor, reducing inflammation and preventing flares in generalized pustular psoriasis, offering new hope for patients.

World Skin Health Day 2025 unites global leaders to advocate for skin health equity, emphasizing the urgent need for accessible dermatological care worldwide.